Eupraxia Pharmaceuticals Inc. (EPRXF) Stock

About Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Inc. operates as a clinical-stage biotechnology firm, focusing its efforts on the discovery, advancement, and commercialization of innovative technologies within the biotech landscape. The company's leading therapeutic compound, EP-104IAR, is currently progressing through Phase II clinical trials. This candidate is designed to address pressing unmet medical needs and provide pain relief for individuals suffering from knee osteoarthritis. Additionally, its potential is being explored for the treatment of osteoarthritis in animal companions, specifically dogs and horses. Eupraxia's development pipeline also features other significant programs, including EP-201, an antibiotic intended to prevent or treat infections following surgical procedures, and EP-105, an extended-release anesthetic aimed at managing post-surgical pain effectively. Furthermore, the company is actively pursuing the development of novel drug candidates for various oncological indications. Founded in 2011, the company was initially known as Plaza Capital Partners Inc. before officially adopting the name Eupraxia Pharmaceuticals Inc. in May 2012. Its principal operations are based in Victoria, Canada.

Eupraxia Pharmaceuticals Inc. is headquartered in CA.

Eupraxia Pharmaceuticals Inc. (EPRXF) stock trades at $3.04 with a market capitalization of $108.29M. The stock is valued at a price-to-earnings (P/E) ratio of -6.15, price-to-book of 2.66, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.93 and $6.78, and currently trades 55.2% below its 52-week high.

On profitability, Eupraxia Pharmaceuticals Inc. generates a return on equity (ROE) of -53.61%, return on capital employed of -34.22%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.eupraxiapharma.com